Exelixis, Inc. (EXEL)
Nasdaq · Healthcare · Biotechnology
$58.85+0.79%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $14.6B
- P/E (trailing)
- 18.6
- Forward P/E
- 13.8
- 52-week range
- $33.76 – $61.14
- 52-week change
- +45.94%
- EPS (trailing)
- $3.17
- Analyst rating
- 2.3 Buy
- Next earnings
- Oct 27, 2026
Fiscal year to Jan 2026
- Revenue
- $2.3B (+6.98%)
- Net income
- $783M
- Operating margin
- 37.6%
- Diluted EPS
- $2.78
- Free cash flow
- $876M
From the company’s annual report on SEC EDGAR.
About Exelixis, Inc.
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan.
Headquarters: Alameda, United States · 1,077 employees · exelixis.com